52.4 F
New York
Monday, November 28, 2022



Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report

Related Articles

Menlo Park, CA, May 25, 2021 –(PR.com)– Life Science Strategy Group (LSSG), the leading strategic consulting firm to the CRO industry, is pleased to announce the launch of its new syndicated report, COVID-19 Impact on the Biopharmaceutical Industry and CRO Outsourcing – 2021 Update. This updated study with 120 biopharmaceutical industry clinical development outsourcing decision makers in the US, Europe and China provides quantitative analysis, metrics, and insights into biopharmaceutical clinical development budgets, activity, outsourcing to CROs and outlook in 2021 vs. the same period in 2020.

This industry first, landmark report also highlights longitudinal analysis of 2021 results vs. 2020. CROs highlighted by respondents in the report include Covance, ICON, IQVIA, PAREXEL, PPD, PRA Health Sciences and Syneos Health among others. According to Jon Meyer, Principal, Life Science Strategy Group, “COVID-19 has certainly turned…

Read more…

Popular Articles